Selective suppression of cytokine secretion in patients with small-cell lung cancer
- 1 November 1995
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 6 (9) , 921-926
- https://doi.org/10.1093/oxfordjournals.annonc.a059360
Abstract
Whether or not cytokine secretion is impaired in patients with small-cell lung cancer (SCLC), is unknown. We therefore investigated whether cytokine secretion by immunocompetent cells may be suppressed in patients with SCLC We determined cytokine secretion by lymphocytes and monocytes in whole blood cell cultures from 58 patients with SCLC, 95 patients with non-small-cell lung cancer (NSCLC), 10 patients with nonmalignant lung disease and from 44 normal healthy individuals by using an enzyme-linked immunosorbent assay (ELISA) specific for the different cytokines measured. Compared to normal controls, immunocompetent cells from patients with SCLC secreted significantly lower amounts of IL-2, IFN α, and IFN γ upon mitogen stimulation. TNF α-secretion was significantly reduced in SCLC extensive disease but not in SCLC limited disease. In contrast, secretion of IL-1 α and IL-1 β was not reduced. In patients with NSCLC, secretion of IL-2 and IFN α was significantly reduced. Reduction of IFN γ secretion was significant in metastasized NSCLC and marginally significant in localized NSCLC. Secretion of TNF α, IL-1 α and IL-1 β was not impaired. In addition, cytokine secretion in SCLC patients substantially improved upon successful reduction of tumor load by chemotherapy but not upon ineffective chemotherapy. Furthermore, TGF β1, suppressed secretion of IL-2, IFN α, IFN γ, TNF α, but not of IL-lα and IL-1 β in whole blood cell cultures from healthy individuals. Suppression of cytokine secretion in patients with SCLC was selective, dependent on tumor load, different from immunosuppression in NSCLC and seemed to be reconstituted upon reduction of tumor load. These results may suggest interactions between tumor cells and the immune system. TGF β1, secreted by SCLC cell lines induced the same selective cytokine suppression as that found in SCLC patients. However, whether or not tumor-derived TGF β1, is a factor inducing selective immunosuppression in SCLC patients is presently unclear.Keywords
This publication has 10 references indexed in Scilit:
- Constitutive secretion of bioactive transforming growth factor β1 by small cell lung cancer cell linesEuropean Journal Of Cancer, 1994
- Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.Journal of Clinical Investigation, 1993
- Impaired cytokine production in whole blood cell cultures of patients with urological carcinomasZeitschrift für Krebsforschung und Klinische Onkologie, 1993
- Expression of transforming growth factor β (TGFβ) receptors and expression of TGFβ1, TGFβ2 and TGFβ3 in human small cell lung cancer cell linesBritish Journal of Cancer, 1993
- Transforming growth factor-β mRNA expression and growth control of human ovarian carcinoma cellsBritish Journal of Cancer, 1992
- Evaluation of a test system for measuring cytokine production in human whole blood cell culturesJournal of Immunological Methods, 1991
- A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance.Proceedings of the National Academy of Sciences, 1990
- A whole-blood technique for testing production of human interferon by leukocytesJournal of Immunological Methods, 1982
- Multiple Comparisons Using Rank SumsTechnometrics, 1964
- A Nonparametric test for the Several Sample ProblemThe Annals of Mathematical Statistics, 1952